ABSTRACT

Introduction

Cardiovascular disease (CVD) is the leading cause of death in western countries. Although surgical outcomes for CVD are dramatically improving with the development of surgical techniques, medications, and perioperative management strategies, adverse postoperative events related to the use of artificial prosthetic materials are still problematic. Moreover, in pediatric patients, using these artificial materials make future re-intervention inevitable due to their lack of growth potential.

Areas Covered

This review focuses on the most current tissue-engineering (TE) technologies to treat cardiovascular diseases and discusses their limitations through reports ranging from animal studies to clinical trials.

Expert Opinion

Tissue-engineered structures, derived from a patient’s own autologous cells/tissues and biodegradable polymer scaffolds, can provide mechanical function similar to non-diseased tissue. However, unlike prosthetic materials, tissue-engineered structures are hypothetically more biocompatible and provide growth potential, saving patients from additional or repetitive interventions. While there are many methods being investigated to develop TE technologies in the hopes of finding better options to tackle CVD, most of these approaches are not ready for clinical use or trials. However, tissue engineering has great promise to potentially provide better treatment options to vastly improve cardiovascular surgical outcomes.

中文翻译：

---

组织工程血管技术发展现状

摘要

介绍

心血管疾病（CVD）是西方国家死亡的主要原因。尽管随着手术技术、药物和围手术期管理策略的发展，心血管疾病的手术结果正在显着改善，但与使用人工修复材料相关的术后不良事件仍然存在问题。此外，在儿科患者中，由于缺乏生长潜力，使用这些人造材料使得未来的重新干预不可避免。

涵盖的领域

这篇综述重点介绍了治疗心血管疾病的最新组织工程 (TE) 技术，并通过从动物研究到临床试验的报告讨论了它们的局限性。

专家意见

源自患者自身的自体细胞/组织和可生物降解的聚合物支架的组织工程结构可以提供与未患病组织相似的机械功能。然而，与假体材料不同，组织工程结构在假设上更具生物相容性并提供增长潜力，从而使患者免于额外或重复的干预。虽然有许多方法正在研究开发 TE 技术，希望找到更好的选择来解决 CVD，但这些方法中的大多数还没有准备好用于临床使用或试验。然而，组织工程很有希望提供更好的治疗选择，以极大地改善心血管手术的结果。